Author

Walter Reinisch

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME

SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY
SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY

HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL
EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Walter Reinisch  et al.

EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL
EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

Walter Reinisch  et al.

BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

Walter Reinisch  et al.

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY
AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY
AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

Walter Reinisch  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Walter Reinisch  et al.

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED ?4?7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDE
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED ?4?7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDE

Walter Reinisch

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Walter Reinisch  et al.

BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Walter Reinisch  et al.

Item 1 - 20 / 49
1
2 3